Core Viewpoint - The collaboration between 英矽智能 (InSilico Medicine) and 深圳衡泰生物科技有限公司 (HengTai Bio) aims to accelerate the global development of ISM8969, a novel NLRP3 inhibitor for treating central nervous system diseases [1] Group 1: Partnership Details - 英矽智能 and 衡泰生物 have entered into a joint development agreement for the ISM8969 project [1] - The agreement grants 衡泰生物 50% rights for research, development, registration, production, and commercialization of ISM8969 globally [1] - 英矽智能 will lead the early clinical development, including the submission of new drug clinical trial applications and the initiation of Phase I clinical trials for Parkinson's disease [1] Group 2: Financial Aspects - 英矽智能 is set to receive over 500 million HKD in total prepayments and milestone payments, including an initial prepayment of 78 million HKD expected within 30 days of the agreement's effective date [1] - The stock price of 英矽智能 increased by nearly 5% during trading, closing at 54.05 HKD with a transaction volume of 20.253 million HKD [1]
港股异动 | 英矽智能(03696)盘中涨近5% 宣布与衡泰生物达成超5亿港元合作